A practical reference on counterion: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-14. Anything still debated is marked as such rather than presented as settled.
Regulatory and accreditation expectations depend on the peptide's intended use. Research reagents may be tested with in-house methods, while pharmaceutical development follows validated procedures and pharmacopeial chapters where applicable. Method validation commonly examines accuracy, precision, specificity, linearity, range, and limits of detection and quantitation. Laboratories accredited to ISO/IEC 17025 must document competence, equipment calibration, and uncertainty. Comparing purity results across laboratories remains difficult because different columns, gradients, detection wavelengths, and integration rules can change reported values; open questions include how best to standardize impurity identification and reporting for diverse peptide products.
Quality control for peptides places purity testing within a documented system that includes specifications, test methods, and acceptance criteria. A certificate of analysis typically reports appearance, chromatographic purity, mass confirmation, and storage conditions. System suitability checks, blank injections, and reference standards help ensure that an analytical run is valid. Traceability requires records of sample preparation, instrument settings, and data processing. No single purity threshold applies to all peptides or uses, so specifications are set according to the intended application and risk assessment.
Sampling and sample preparation influence measured purity. Peptides are often hygroscopic, so weighing should occur quickly under controlled humidity to avoid water uptake. Complete dissolution in a suitable solvent is necessary before injection; undissolved material can block columns or distort results. Filtration removes particulates but may also remove aggregates if the filter pore size is too small. Impurities can originate from synthesis, cleavage, purification, or storage, and forced degradation under heat, light, oxidation, or pH extremes can help identify degradation pathways.
Quality control relies on predefined specifications rather than a single purity number. A certificate of analysis typically lists the test method, acceptance limit, and measured result for each attribute. Common specifications include appearance, peptide content, water content, counterion identity, and related substances. Limits are set according to the peptide's intended use and the capability of the analytical method. A result outside a limit triggers investigation, not automatic rejection, because method variability and sample handling can affect outcomes.
Sample handling influences measured purity. Lyophilized peptides are hygroscopic and can absorb water, changing weight-based calculations, while repeated freeze-thaw cycles may promote aggregation or degradation. Dissolved samples should be prepared fresh when possible and protected from light and heat. In purity testing, the same handling conditions should apply to standards and samples. Stability-indicating methods are designed to separate degradation products from the parent peptide, though open questions remain about how accelerated stability data predict long-term behavior for every sequence.
Peptide purity testing distinguishes several impurity classes. Related substances include truncated sequences, deletion peptides, and diastereomers formed during synthesis, while residual solvents, counterions, and water are not peptide-related but affect mass balance. Aggregates and oxidation products can arise during storage. Each class requires different analytical approaches, and a complete purity profile combines separation, mass measurement, and orthogonal assays. Reporting only a single percentage can obscure which impurities are present, so the profile should name the methods and limits used.
| Property | Value | Notes |
|---|---|---|
| Quality specification | Lot-specific; often 95% or greater by HPLC area | Thresholds depend on intended use and analytical method. |
| Documentation | Certificate of analysis | Includes method details, results, and storage guidance. |
| Sample preparation | Dissolve in suitable solvent; filter if needed | Avoid contamination and ensure complete dissolution. |
| Method validation | Accuracy, precision, specificity, linearity | Required for regulated or accredited testing. |
| Common impurity classes | Deletion, oxidation, deamidation, truncation | Identified by chromatography and mass spectrometry. |
Interpreting chromatographic purity requires attention to detection limits and response factors. Peptides without aromatic residues may absorb weakly at 280 nm, so 214 nm is often preferred, but mobile-phase additives and solvents also absorb at low wavelengths. Co-eluting impurities with different molar absorptivities can produce area percentages that differ from mass percentages. Integration parameters, peak tailing, and baseline choice further affect reported values. For these reasons, method details belong alongside any purity figure, and orthogonal methods are needed to confirm identity and impurity profiles.
Reverse-phase high-performance liquid chromatography is the most common primary method for peptide purity testing. The peptide mixture passes through a hydrophobic stationary phase, and components elute according to differences in hydrophobicity. A mobile phase of water and acetonitrile, often with trifluoroacetic acid as an ion-pairing agent, improves peak shape and retention. Ultraviolet detection at 214 nm records the peptide backbone absorbance, and the main peak area is divided by the total peak area to give an area-percent purity value.
Quality control specifications for peptides typically include appearance, identity, purity by RP-HPLC, water content, counterion content, and residual trifluoroacetic acid. Karl Fischer titration measures water, while ion chromatography or elemental analysis can quantify counterions. Purity specifications may be set at 95% or 98% area percent, but the appropriate threshold depends on the application. For research reagents, a lower purity may be acceptable if identity is confirmed. For assays sensitive to impurities, higher purity and orthogonal testing are often required.
Handling and storage influence measured purity, and peptides can oxidize, deamidate, aggregate, or adsorb to surfaces over time. Lyophilized powders stored at -20 °C or lower are generally more stable than solutions, though some sequences require different conditions. Repeated freeze-thaw cycles can promote aggregation and loss, so testing after storage checks whether purity has changed. Stability-indicating methods compare stressed and unstressed samples to detect degradation pathways. Light exposure and pH can also accelerate modification.
Peptide purity testing sits within a broader quality control framework. Release testing commonly includes appearance, identity, purity, peptide content, counterion content, water content, and residual solvents. Elemental impurities and microbiological attributes may be examined when relevant to the manufacturing route. Pharmacopoeial monographs and general chapters provide methods and acceptance criteria for some peptides, but many research-grade materials are not covered by such standards. Method validation establishes specificity, linearity, accuracy, precision, range, and robustness for each test.
Handling practices strongly affect measured purity and sample integrity. Many peptides are hygroscopic, susceptible to oxidation, or prone to adsorption on glass and plastic surfaces. Lyophilized powders are typically stored desiccated at -20 °C or below, while solutions may require colder storage and minimized freeze-thaw cycles. Peptides containing cysteine, methionine, or tryptophan can degrade through oxidation or disulfide exchange. Working aliquots reduce repeated exposure to moisture and temperature fluctuations during routine analysis.
Mass spectrometry provides an identity check that complements chromatographic purity. Electrospray ionization or matrix-assisted laser desorption/ionization measures the mass-to-charge ratio of intact peptides. A match to the expected molecular mass supports correct sequence length and terminal groups. Mass accuracy alone does not prove that every peak in a liquid chromatogram is the target peptide. It also does not directly quantify how much water or counterion remains in a lyophilized powder.
Orthogonal methods reduce the chance that a single technique misses an impurity. Capillary electrophoresis separates by charge-to-size ratio and can resolve variants that co-elute under one set of HPLC conditions. Amino acid analysis reports composition after hydrolysis and confirms the presence of expected residues. Karl Fischer titration measures water content, while ion chromatography can quantify counterions. No single number captures all aspects of sample quality, so reports often combine several measurements.
Peptide purity testing uses separation methods to estimate the proportion of a sample that corresponds to the target sequence. Reverse-phase high-performance liquid chromatography is the most common technique, separating peptides by hydrophobicity on a nonpolar column. Ultraviolet detection at 214 nm records peptide bonds and aromatic residues. The resulting chromatogram is reported as area percent, which reflects relative absorbance rather than absolute mass. This distinction matters because water, counterions, and residual solvents do not appear in the peptide peak.
Ectopic fat is the storage of triglycerides in tissues other than adipose tissue, that are supposed to contain only small amounts of fat, such as the liver, skeletal muscle, heart, and pancreas. This can interfere with cellular functions and hence organ function and is associated with insulin resistance in type 2 diabetes. It is stored in relatively high amounts around the organs of the abdominal cavity, but is not to be confused with visceral fat. The specific cause for the accumulation of ectopic fat is unknown. The cause is likely a combination of genetic, environmental, and behavioral factors that are involved in excess energy intake and decreased physical activity. Substantial weight loss can reduce ectopic fat stores in all organs and this is associated with an improvement of the function of those organs. In the latter case, non-invasive weight loss interventions like diet or exercise can decrease ectopic fat (particularly in heart and liver) in overweight or obese children and adults.
Proteins consist of chains of amino acids which spontaneously fold to form the three dimensional (3-D) structures of the proteins. The 3-D structure is necessary to understanding the biological function of the protein. Protein structures can be determined experimentally through techniques such as X-ray crystallography, cryo-electron microscopy and nuclear magnetic resonance (NMR), which are all expensive and time-consuming. Such efforts, using the experimental methods, have identified the structures of about 170,000 proteins over the last 60 years, while there are over 200 million known proteins across all life forms. Over the years, researchers have applied numerous computational methods to predict the 3D structures of proteins from their amino acid sequences, accuracy of such methods in best possible scenario is close to experimental techniques (NMR) by the use of homology modeling based on molecular evolution. CASP, which was launched in 1994 to challenge the scientific community to produce their best protein structure predictions, found that GDT scores of only about 40 out of 100 can be achieved for the most difficult proteins by 2016. AlphaFold started competing in the 2018 CASP using an artificial intelligence (AI) deep learning technique.
Being the smallest alkali metal, lithium forms the widest variety of and most stable organometallic compounds, which are bonded covalently. Organolithium compounds are electrically non-conducting volatile solids or liquids that melt at low temperatures, and tend to form oligomers with the structure (RLi)x where R is the organic group. As the electropositive nature of lithium puts most of the charge density of the bond on the carbon atom, effectively creating a carbanion, organolithium compounds are extremely powerful bases and nucleophiles. For use as bases, butyllithiums are often used and are commercially available. An example of an organolithium compound is methyllithium ((CH3Li)x), which exists in tetrameric (x = 4, tetrahedral) and hexameric (x = 6, octahedral) forms. Organolithium compounds, especially n-butyllithium, are useful reagents in organic synthesis, as might be expected given lithium's diagonal relationship with magnesium, which plays an important role in the Grignard reaction. For example, alkyllithiums and aryllithiums may be used to synthesise aldehydes and ketones by reaction with metal carbonyls. The reaction with nickel tetracarbonyl, for example, proceeds through an unstable acyl nickel carbonyl complex which then undergoes electrophilic substitution to give the desired aldehyde (using H+ as the electrophile) or ketone (using an alkyl halide) product.
2,5-DKPs are synthesized by a variety of organisms including humans. In general, they arise by the action of a tRNA-dependent cyclodipeptide synthases, a type of enzyme responsible for creating a cyclic amide linkage between two peptides. The enzymes cyclodipeptide oxidase and S-adenosyl-methionine-dependent O/N methyltransferases act in tandem to chemically modify cyclic dipeptides. 2,5-Diketopiperazines are typically prepared by one of three methods: amide bond formation, N-alkylation and C-acylation.
Sources: en.wikipedia.org
Newton has been a major driver in the PKC research field since the 1980s, working originally with Daniel E. Koshland Jr. She helped define the multiple different mechanisms of PKC regulation by phosphorylation and its interaction with specific membrane phospholipids, such as phosphatidylserine She has also made important discoveries in the protein phosphatase field, discovering and naming PHLPP (PH domain and Leucine rich repeat Protein Phosphatases), which regulate intracellular signaling through dephosphorylation of AKT. As of 2020, Newton has published over 190 peer-reviewed research articles that have been cited more than 25,000 times, been awarded 1 patent and co-edited two books on protein biochemistry and PKC. Her work straddles basic research and has illuminated understanding of PKC in Alzheimer's disease and as a tumor suppressor in human cancers
Binding of a ligand to a binding site on protein often triggers a change in conformation in the protein and results in altered cellular function. Hence binding site on protein are critical parts of signal transduction pathways. Types of ligands include neurotransmitters, toxins, neuropeptides, and steroid hormones. Binding sites incur functional changes in a number of contexts, including enzyme catalysis, molecular pathway signaling, homeostatic regulation, and physiological function. Electric charge, steric shape and geometry of the site selectively allow for highly specific ligands to bind, activating a particular cascade of cellular interactions the protein is responsible for.
The human form of IAPP has the amino acid sequence KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY, with a disulfide bridge between cysteine residues 2 and 7. Both the amidated C-terminus and the disulfide bridge are necessary for the full biological activity of amylin. IAPP is capable of forming amyloid fibrils in vitro. Within the fibrillization reaction, the early prefibrillar structures are extremely toxic to beta-cell and insuloma cell cultures. Later amyloid fiber structures also seem to have some cytotoxic effect on cell cultures. Studies have shown that fibrils are the end product and not necessarily the most toxic form of amyloid proteins/peptides in general. A non-fibril forming peptide (1–19 residues of human amylin) is toxic like the full-length peptide but the respective segment of rat amylin is not. It was also demonstrated by solid-state NMR spectroscopy that the fragment 20-29 of the human-amylin fragments membranes. Rats and mice have six substitutions (three of which are proline substitutions at positions 25, 28 and 29) that are believed to prevent the formation of amyloid fibrils, although not completely as seen by its propensity to form amyloid fibrils in vitro. Rat IAPP is nontoxic to beta-cells when overexpressed in transgenic rodents.
Genetically modified organism History of biotechnology An Asilomar Moment Archived 10 July 2013 at the Wayback Machine Original Asilomar Genetics Guidelines “Asilomar Conference.” Provides another summary of the Asilomar Conference. The Basics of Recombinant DNA provides an introduction to the science behind recombinant DNA. The Recombinant DNA Debate Archived 31 March 2007 at the Wayback Machine provides more details about the history of the debate surrounding the use of recombinant DNA technology. “Paul Berg: The 1980 Nobel Prize in Chemistry – Autobiography.” Provides an autobiography about Paul Berg. Science History Institute: The story of the 1975 Asilomar Conference on Recombinant DNA
The AlphaFold Protein Structure Database (AlphaFold DB) is a collaborative project with Google DeepMind to make predicted protein structures from the AlphaFold AI system freely available to the scientific community. The first release of the database was in 2021; as of 2024, AlphaFold DB provides access to over 214 million protein structures. National Center for Biotechnology Information (NCBI), United States National Library of Medicine National Institute of Genetics (DNA Data Bank of Japan) Swiss Institute of Bioinformatics (SIB: Expasy) Australia Bioinformatics Resource BIG Data Center (National Genomics Data Center), Beijing Institute of Genomics, Chinese Academy of Sciences Alternative splicing and transcript diversity database BioJS - open-source project for bioinformatics data on the web BioSamples European Molecular Biology Organization European Nucleotide Archive
Sources: en.wikipedia.org
Adrenomedullin (ADM) is a peptide hormone that plays an important role in various physiological processes throughout the human body. Initially discovered in 1993 from a pheochromocytoma, a tumor of the adrenal medulla, this 52-amino acid peptide is now recognized for its diverse effects, including vasodilation, regulation of blood pressure, and maintenance of the vascular system. ADM is widely expressed in tissues and also found in the circulation, exerting its influence on the cardiovascular, lymphatic, and endocrine systems, as well as demonstrating anti-inflammatory and tissue-protective properties. In humans, ADM is encoded by the ADM gene. A similar peptide named adreomedullin2 was reported in rats in 2004, which exhibits a similar function.
Andexanet alfa is a biologic agent, a recombinant modified version of human activated factor X (FXa). Andexanet alfa differs from native FXa due to the removal of a 34 residue fragment that contains the Gla domain. This modification reduces andexanet alfa's anticoagulant potential. Additionally, a serine to alanine (S419A) mutation in the active site eliminates its activity as a prothrombin to thrombin catalyst, but still allows the molecule to bind to FXa inhibitors. FXa inhibitors bind to andexanet alfa with the same affinity as to natural FXa. As a consequence, in the presence of andexanet alfa, natural FXa is partially freed, which can lead to effective hemostasis. In other words, it acts as a decoy receptor. Andexanet alfa reverses effect of all anticoagulants that act directly through FXa or by binding antithrombin III. The drug is not effective against factor IIa inhibitor dabigatran. Its activity is measured using the anti-Xa test, which is utilized to determine the amount of available factor Xa for coagulation
The AlphaFold Protein Structure Database (AlphaFold DB) is a collaborative project with Google DeepMind to make predicted protein structures from the AlphaFold AI system freely available to the scientific community. The first release of the database was in 2021; as of 2024, AlphaFold DB provides access to over 214 million protein structures. National Center for Biotechnology Information (NCBI), United States National Library of Medicine National Institute of Genetics (DNA Data Bank of Japan) Swiss Institute of Bioinformatics (SIB: Expasy) Australia Bioinformatics Resource BIG Data Center (National Genomics Data Center), Beijing Institute of Genomics, Chinese Academy of Sciences Alternative splicing and transcript diversity database BioJS - open-source project for bioinformatics data on the web BioSamples European Molecular Biology Organization European Nucleotide Archive
Amylin, or islet amyloid polypeptide (IAPP), is a 37-residue peptide hormone. It is co-secreted with insulin from the pancreatic β-cells in the ratio of approximately 100:1 (insulin:amylin). Amylin plays a role in glycemic regulation by slowing gastric emptying and promoting satiety, thereby preventing spikes in blood glucose levels after a meal. IAPP is processed from an 89-residue coding sequence. Proislet amyloid polypeptide (proIAPP, proamylin, proislet protein) is produced in the pancreatic beta cells (β-cells) as a 67 amino acid, 7404 Dalton pro-peptide and undergoes post-translational modifications including protease cleavage to produce amylin.
Sources: en.wikipedia.org
A certificate of analysis reports test results, methods, and specifications for a peptide lot. It often includes appearance, purity by chromatography, mass confirmation, and storage recommendations. It supports quality assessment but does not by itself guarantee suitability for every application.
Impurities are separated by chromatography and then characterized by mass spectrometry, sometimes with tandem mass spectrometry or sequencing. Common impurities include deletion peptides, oxidized forms, deamidated forms, and residual solvents. Identification can be challenging when impurities co-elute or are present at very low levels.
Storage conditions can change measured purity because degradation increases impurity peaks over time. Temperature, moisture, light exposure, and repeated freeze-thaw cycles are common influences. Re-testing after storage may therefore produce different results from the original certificate of analysis.
A related substance is a peptide-like impurity that resembles the target sequence, such as a truncated or modified form. It is often reported as individual and total area percent.